Radiopharm Forms Collaboration to Develop PD-L1 Diagnostic/Therapeutic Antibody
publication date: Aug 4, 2022
Australia’s Radiopharm Theranostics will collaborate with Lantheus, a Boston diagnostic company, to develop a PD-L1 nanobody that is a diagnostic and a therapy. NM-01 is made using genetically engineered camelid-derived single domain antibodies, that can be labelled with low-dose radioisotopes as a diagnostic and with higher radioisotope doses to treat multiple tumor types. Radiopharm has global rights to NM-01 as a therapy from NanoMab of the UK, which developed the therapy, and it will have China rights to the diagnostic from Lantheus. F.inancial details of the agreement were not disclosed. More details....
Stock Symbol: (ASX: RAD)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.